Micafungin Pharmazac, 100 Mg (Micafungin)

Micafungin inhibits the enzyme β‑(1,3)‑D‑glucan synthase, blocking the synthesis of β‑(1,3)‑D‑glucan, a vital component of the fungal cell wall. This disruption compromises cell wall integrity, leading to osmotic instability and fungal cell death, providing a targeted antifungal effect with limited impact on human cells.

The specific dose of Micafungin Pharmazac, 100 mg is determined by the prescribing clinician based on the patient’s infection type, severity, weight, renal and hepatic function, and other clinical factors. Healthcare providers follow approved guidelines and adjust the regimen as needed for each individual case.

The safety of Micafungin in pregnancy and lactation has not been established; it is classified as pregnancy category unknown. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and assists with import documentation.

Compared with azole antifungals, micafungin belongs to the echinocandin class and targets the fungal cell wall rather than ergosterol synthesis, offering a different safety profile and activity against many azole‑resistant Candida species. Unlike polyenes, it has lower nephrotoxicity, making it a valuable option for patients with renal concerns.

Micafungin Pharmazac, 100 mg should be stored at 2 °C to 8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the product. Maintaining the cold chain preserves drug stability and potency until the time of administration.

The medication is supplied as a sterile powder for injection that must be reconstituted with the appropriate diluent and administered intravenously over a specified infusion period. Administration is performed by qualified healthcare personnel in a clinical setting, following aseptic technique and the prescribing information for infusion rate and monitoring.

The most serious risks include hepatotoxicity, severe hypersensitivity reactions such as anaphylaxis, and rare infusion‑related events like hypotension or bronchospasm. Patients should be monitored for signs of liver dysfunction, allergic response, and hemodynamic changes during and after the infusion, and therapy should be discontinued if serious adverse events occur.

Micafungin is contraindicated in patients with a known hypersensitivity to micafungin or any component of the formulation. Caution is also advised for individuals with pre‑existing severe liver disease, and it should be avoided in pregnant or breastfeeding women unless the clinical benefit justifies potential risks. Clinical judgment determines suitability.